News & articles

Presented at the 24th Congress of the European Hematology Association (EHA), Promedior, Inc. announced today that positive safety and early efficacy clinical data was proven during their Phase 2 study of PRM-151 in myelofibrosis (MF) patients who were ineligible for Ruxolitinib or had failed the drug. Promedior looks forward to advancing the clinical program for PRM-151 in both MF and… Read More »PROMEDIOR PRESENTS POSITIVE DATA FROM A PHASE 2 STUDY OF PRM-151 IN MF PATIENTS

How does MDM2 inhibition work to treat myeloproliferative neoplasms (MPNs)? What are the goals of this treatment approach? Renowned experts Dr. Srdan Verstovsek and Dr. Jason Gotlib discuss MDM2 inhibition as an avenue for the treatment of MPNs and share information on an upcoming MDM2 clinical trial for patients living with myelofibrosis (MF) and polycythemia vera… Read More »HOW DOES MDM2 INHIBITION WORK TO TREAT MPNS?

Researchers at the American Association for Cancer Research recently published an article, “Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T Cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms,” highlighting the restoration of T-cells specific to fighting the CALR mutation in MPN patients. Utilization of checkpoint blockades confirmed mut-CALR as an effective immunogen that can be… Read More »PROMISING RESULTS OF NEW AACR STUDY

Since the development of the JAK1/2 inhibitor ruxolitinib, our understanding of MPNs has come a long way. Researchers Bing Li, Raajit K. Rampal, and Zhijian Xiao document the targeted therapies currently in various stages of development, with the promising effects of reducing myelosuppression, greater selectivity for JAK1/2, and the ability to overcome JAK inhibitor persistence.… Read More »THE ADVANCEMENT OF TARGETED THERAPY

We know that myeloproliferative neoplasms may occasionally run in families, but what we don’t know is why. The Fleischman Lab, headed by Dr. Angela Fleischman, MD. PhD. in Irvine, CA is seeking to answer that question. Through the MPN Family Study, Dr. Fleischman is working to identify why some families are more likely to get… Read More »THE MPN FAMILIAL STUDY

Exciting drug development news for Myelofibrosis patients, aimed at people whose disease had progressed or did not see an adequate response while on Ruxolitinib. A researcher at Mt. Sinai in this video discusses observations from their clinical trial with the drug CPI-0610.  Investigators saw improvement in anemia as well as improvement in bone marrow in some… Read More »CPI-0610 DEMONSTRATES ACTIVITY IN MF PATIENTS AFTER RUXOLITINIB FAILURE

The American Society of Hematology presented Emmanuelle Passegué, Ph.D., of Columbia University Irving Medical Center in New York City with the 2019 William Dameshek Prize for her outstanding contribution to the field of hematology. “Dr. Passegué, director of Columbia Stem Cell Initiative at Columbia University Irving Medical Center and Alumni Professor of Genetics and Development at… Read More »ASH AWARDS THE 2019 WILLIAM DAMESHEK PRIZE

The approval of Inrebic (fedratinib) for myelofibrosis is the first FDA-approval of a new therapy for myelproliferative neoplasms in nearly a decade. We at the MPN Research Foundation are thrilled to see more options for people living with myelfobrosis who have long suffered with few options for relief. We hope this approval ushers in a… Read More »FEDRATINIB APPROVED FOR MYELOFIBROSIS!

In an article published by CURE Today, MPN Research Foundation’s Executive Director, Michelle Woehrle, sat down with Kristie L. Kahl, to discuss the FDA’s approval of new Myelofibrosis drug Inrebic (fedratinib), the first approved drug for the disease in nearly a decade.  “We at the MPN Research Foundation are thrilled to see more options for people living with myelofibrosis… Read More »MPNRF QUOTED IN CURE TODAY MAGAZINE

Myeloproliferative neoplasms (MPN) patient advocacy organizations are working together across borders to ensure that people living with an MPN (polycythemia vera, essential thrombocythemia and myelofibrosis) will have their treatment needs met by partnering with one another. These organizations are driven by the need to ensure a better understanding about the origins of MPN in hopes… Read More »RESEARCH INTO RARE BLOOD CANCERS CALLED MYELOPROLIFERATIVE NEOPLASMS GOES GLOBAL